전체 8345
-
- Epigenetic and genetic regulation of V(D)J recombination
-
- - Ann Feeney (2010/11/18)
- - Category : Immunology
Epigenetic and genetic regulation of V(D)J recombination
-
- NIH Consensus Development Conference: Inhaled Nitric Oxide Therapy For Premature Infants - Day 2
-
- - NICHD and OMAR (2010/11/18)
- - Category : Conferences
- Babies born before the 28th week of pregnancy？？？more than 30,000 per year in the United States？？？are particularly vulnerable to breathing problems due to their underdeveloped lungs. Nitric oxide is sometimes used to treat infants with severe breathing problems, and inhaled nitric oxide therapy was approved by the U.S. FDA in 2000 to treat term and near-term infants (born after the 33rd week of pregnancy) with respiratory failure. Since its approval, researchers have examined expanding the use of inhaled nitric oxide therapy to treat premature babies born at less than 34 weeks？？？ gestation. The National Institutes of Health is convening a Consensus Development Conference October 27-29, 2010 to assess the available scientific evidence related to the benefits and risks of inhaled nitric oxide therapy for premature infants.
NIH Consensus Development Conference: Inhaled Nitric Oxide Therapy For Premature Infants - Day 2
-
- GCP and Responsibilities of the PI and Research Team
-
- - Dr. Susan Thompson (2010/11/18)
- - Category : Special
- Dr. Susan Thompson is coming from the FDA to give a lecture on GCP and Responsibilities of the PI and Research Team when conduction FDA regulated clinical research.
GCP and Responsibilities of the PI and Research Team
-
- Anita B. Roberts Lecture: Integrating T cell signals
-
- - Dr. Pamela Schwartzberg (2010/11/18)
- - Category : Anita B. Roberts
- Dr. Pamela Schwartzberg will give the ninth lecture in the Anita B. Roberts lecture series, which highlights outstanding research achievements of women scientists in the Intramural Research Program.
Anita B. Roberts Lecture: Integrating T cell signals
-
- NIH 2010 Disability Awareness Month Observance (NIH Only)
-
- - Ms. Bonnie St. John (2010/11/18)
- - Category : Disability (NIH Only)
- Talent Has No Boundaries: Workforce diversity includes people with disabilities
NIH 2010 Disability Awareness Month Observance (NIH Only)
-
- NIH Consensus Development Conference: Inhaled Nitric Oxide Therapy For Premature Infants - Day 3
-
- - NICHD and OMAR (2010/11/18)
- - Category : Conferences
- Babies born before the 28th week of pregnancy？？？more than 30,000 per year in the United States？？？are particularly vulnerable to breathing problems due to their underdeveloped lungs. Nitric oxide is sometimes used to treat infants with severe breathing problems, and inhaled nitric oxide therapy was approved by the U.S. FDA in 2000 to treat term and near-term infants (born after the 33rd week of pregnancy) with respiratory failure. Since its approval, researchers have examined expanding the use of inhaled nitric oxide therapy to treat premature babies born at less than 34 weeks？？？ gestation. The National Institutes of Health is convening a Consensus Development Conference October 27-29, 2010 to assess the available scientific evidence related to the benefits and risks of inhaled nitric oxide therapy for premature infants.
NIH Consensus Development Conference: Inhaled Nitric Oxide Therapy For Premature Infants - Day 3
-
- Strengthening the Culture of Responsibility with Respect to Dual Use Research and Biosecurity
-
- - NIH (2010/11/18)
- - Category : National Science Advisory Board for Biosecurity
- Satellite Session of ？？？An International Workshop to Assess
Implications of Scientific and Technological Developments for Biosecurity？？？
To engage attendees who have an interest in life sciences research (including multidisciplinary life science research), focusing on the issue of a culture of responsibility.
Strengthening the Culture of Responsibility with Respect to Dual Use Research and Biosecurity
-
- SEER-Medicare Data Training Workshop - November 2010 (Day 1)
-
- - Dr. Joan Warren, National Cancer Institute (2010/11/18)
- - Category : Conferences
- The purpose of the training is to assist investigators who are new to the SEER-Medicare data in understanding some of the methodological issues associated with using these data for epidemiologic and health services research
SEER-Medicare Data Training Workshop - November 2010 (Day 1)
-
- NCI Board of Scientific Advisors - November 2010
-
- - Dr. Paulette S. Gray (2010/11/18)
- - Category : NCI Board of Scientific Advisors
- The 47th Meeting of the National Cancer Institute Board of Scientific Advisors.
NCI Board of Scientific Advisors - November 2010
-
- Synaptic Transmission at the Ribbon Synapses of the Eye and Ear
-
- - Henrique von Gersdorff, Ph.D., Vollum Institute, Oregon Health and Science University (2010/11/18)
- - Category : Neuroscience
- Neuroscience Seminar Series
Sensory information is conveyed by neurons specialized to faithfully transmit large amounts of information at high rates. A key event in synaptic transmission is the release of neurotransmitter via vesicle fusion at synaptic terminals. Direct studies of synaptic terminals have been hampered by technical constraints. However, using high time resolution patch-clamp and membrane capacitance measurements, Dr. Von Gersdorff Lab has studied the kinetics of vesicle fusion (exocytosis) and subsequent membrane retrieval (endocytosis) in single, live synaptic terminals from bipolar cells of the goldfish retina and from hair cells of the frog amphibian papilla. These cells have compact ribbon-type active zones that contain a large pool of releasable vesicles suitable for the transfer of high bandwidths of information. Following short depolarizations, a fast form of endocytosis can be observed, indicating that synaptic vesicle membrane is quickly re-internalized after vesicle fusion. They are presently investigating mechanisms for short-term synaptic plasticity at reciprocal synapses in retinal slices, and multivesicular release at the hair cell synapse using capacitance measurements together with paired recordings of hair cells and their afferent fibers.
To study conventional active zone synapses, the lab has been examining the calyx of Held nerve terminal, a pivotal element in the auditory brainstem circuitry that computes sound source localization. Precise timing of action potential discharges is essential for accomplishing this task. Nevertheless, the mechanisms that modulate and preserve the timing of spikes are poorly understood. Dr. Von Gersdorff Lab is studying these mechanisms and short-term forms of plasticity at this synapse. The large size of the calyx terminal allows them to patch-clamp the terminal and the postsynaptic cell simultaneously, and thus to measure Ca2+ currents, presynaptic capacitance changes, and glutamate release. This direct access to the terminal allows the lab to study the kinetics of synaptic vesicle exocytosis and endocytosis, neurotransmitter reuptake, and the modulation of neuronal output patterns by presynaptic receptors and the Na+/K+-ATPase pump. Presently, the lab is focused on developmental changes that fine-tune auditory synapses for high frequency firing, and developing techniques for imaging the fast dynamics of Ca2+ and Na+ ions in the nerve terminal and axonal afferent fibers.
Synaptic Transmission at the Ribbon Synapses of the Eye and Ear
-
- TRACO: Angiogenesis and Genomics
-
- - E.Zudaire and J. Khan (2010/11/18)
- - Category : TRACO
- For more information, visit
http://ccr.cancer.gov/careers/traco.asp
TRACO: Angiogenesis and Genomics
-
- SEER-Medicare Data Training Workshop - November 2010 (Day 2)
-
- - Dr. Joan Warren, National Cancer Institute (2010/11/18)
- - Category : Conferences
- The purpose of the training is to assist investigators who are new to the SEER-Medicare data in understanding some of the methodological issues associated with using these data for epidemiologic and health services research
SEER-Medicare Data Training Workshop - November 2010 (Day 2)
-
- Predictors of Breast Cancer Risk in BRCA1 Carriers (NIH Only)
-
- - Steven A. Narod, M.D., FRCPC, University of Toronto (2010/11/18)
- - Category : NCI CCR Grand Rounds (NIH Only)
- Dr. Narod completed medical school at the University of British Columbia, followed by an internship at McGill University-Jewish General Hospital. He completed his residency in community medicine at the University of Ottawa. Dr. Narod then did two fellowships; one in medical genetics at the Hospital for Sick Children in Toronto and one in cancer epidemiology as an International Agency for Research on Cancer fellow in Lyon, France. He worked at McGill University as an assistant professor before working as an associate professor at the University of Toronto. Dr. Narod is currently the director of the Familial Breast Cancer Research Unit at the Women？？？s College Research Institute in Toronto and is a Tier I Canada Research Chair in Breast Cancer. He is also a professor in the department of public health sciences at the University of Toronto, with cross appointments in the medicine, surgery, pathology and obstetrics and gynecology departments. He co-discovered the BRCA1 and BRCA2 genes and was the first to describe recurrent Jewish mutations. His research goal is to translate emerging knowledge on hereditary cancers into more effective strategies for the prevention and management of breast and ovarian cancers. In addition, he is working on delineating the gene/environment interactions that may underlie hereditary breast cancer in the identification of potential modifiers of high-risk cancers. Dr. Narod has studied hereditary aspects of cancer susceptibility for 20 years and has authored more than 400 papers on this topic. Overall, Dr. Narod is the most cited scientist in the world in the field of breast cancer, and his research has been instrumental in furthering understanding of the role of hereditary factors in breast and ovarian cancers.
NCI？？？s Center for Cancer Research (CCR) Grand Rounds is a weekly lecture series addressing current research in clinical and molecular oncology. Speakers are leading national and international researchers and clinicians proposed by members of the CCR Grand Rounds Planning Committee and others within the CCR community and approved by the CCR Office of the Director. Lectures occur every Tuesday from 8:00 to 9:00 a.m. in Lipsett Amphitheater in the Clinical Center building on the NIH campus September through July with exceptions around holidays and major cancer meetings. CME credit available via sign-up sheets in the lecture hall and at designated video-bridge sites only.
Predictors of Breast Cancer Risk in BRCA1 Carriers (NIH Only)
-
- Li-Fraumeni Syndrome Workshop - 2010
-
- - NIH Office of Rare Disease and the National Cancer Institute (2010/11/18)
- - Category : Conferences
- This meeting will bring together intramural and extramural clinicians and scientists to review the existing knowledge regarding Li-Fraumeni syndrome (LFS), to share current research projects, and to identify areas, such as cancer screening and risk reduction interventions, in which further research is needed. The meeting will also serve as a starting point for the creation of a LFS research consortium.
- Video Segment for NCI Cancer Bulletin.
Li-Fraumeni Syndrome Workshop - 2010
-
- JATS Conference - Day 2
-
- - Jeff Beck (2010/11/18)
- - Category : Conferences
- Journal Article Tag Suite Conference
JATS Conference - Day 2
-
- FDA Public Workshop on Cell and Gene Therapy
-
- - FDA (2010/11/18)
- - Category : Conferences
- The FDA will convene a one-day workshop to facilitate an exchange of information about best practices in conducting cell and gene therapy clinical trials in pediatric populations. Cellular and gene therapies are the subject of great interest as novel products that potentially may improve the lives of patients by restoring lost function and modifying the nature and course of diseases. However, these therapies are not without risks: indeed, the novelty of these products contributes to their real and potential risks. Conducting clinical trials with novel products in pediatric patients requires special scrutiny to ensure that the rights of subjects are protected and that potential risks and benefits are appropriately balanced.
The purpose of the workshop is to gather information from Institutional Review Boards (IRBs), gene and cellular therapy clinical researchers, and other stakeholders regarding best practices related to cell and gene therapy clinical trials in pediatric populations, as well as challenges and considerations in the review of these clinical trials.
The workshop will include presentations on cell and gene therapy clinical trials in pediatric populations. The workshop will include panel discussions regarding best practices related to cell and gene therapy clinical trials in pediatric populations including those related to: (1) evaluating these novel therapeutic products prior to initiating pediatric clinical studies; (2) identifying and minimizing risks associated with the administration of cell and gene therapy products in pediatric populations; (3) obtaining informed consent and assent; and (4) conducting continuing review, of cell and gene therapy products in pediatric populations. The workshop also will include panel discussions addressing the challenges and considerations in the review of cell and gene therapy clinical trials in pediatric populations and the role of institutional review boards.
FDA Public Workshop on Cell and Gene Therapy
-
- Basal stem cells of the mouse and human lung: their role in health and disease
-
- - Brigid L.M. Hogan, Ph.D. FRS, Duke University (2010/11/18)
- - Category : Stem Cell
- The Stem Cell Interest Group was established to enhance communication and to foster collaboration among scientists from varying disciplines interested in stem cells. Topics of interest include fundamental stem cell biology, ontogeny, gerontology, and the therapeutic potential of stem cells. The SCIG serves as an open forum for discussion and dissemination of knowledge about all aspects of stem cell biology
For more information, visit
http://www.cellbio.duke.edu/faculty/research/hogan.html
http://sigs.nih.gov/scig/Pages/default.aspx
Basal stem cells of the mouse and human lung: their role in health and disease
-
- Redox Biology: Carcinogenesis and Epidemiology
-
- - G. Yeh and S. Ambs (2010/11/18)
- - Category : Redox Biology
- For more information, visit
http://ccr.cancer.gov/careers/courses/rb/
Redox Biology: Carcinogenesis and Epidemiology
-
- Systems Approaches to Medicine and Cancer
-
- - Dr. Leroy Hood, M.D., Ph.D., Co-founder, Institute for Systems Biology and inventor of the DNA sequencer (2010/11/18)
- - Category : Special
- Dr. Hood, Co-founder of the Institute for Systems Biology and inventor of the DNA sequencer, will address the application of systems approaches to cancer research, interpretation of signal versus noise, the use of single cell measurements, data integration, and the current and future states of systems biology.
Biography
Dr. Hood is recognized around the world for leading the team at Caltech in the 1980s that invented the high-speed DNA sequencing machines that made the Human Genome Project possible. In 2007, he was elected into the Inventors Hall of Fame for the automated DNA sequencer.
Dr. Hood？？？s research has focused on the study of molecular immunology, biotechnology and genomics. Currently, he is pioneering the idea that the systems approach to disease, emerging technologies, and powerful new computational and mathematical tools will move medicine from its current reactive mode to a predictive, preventive, personalized and participatory mode (P4 medicine) over the next 5-20 years. He has published more than 700 articles in peer-reviewed journals and co-authored textbooks in biochemistry, immunology, molecular biology and genetics, and is just finishing a textbook on systems biology.
His lifelong contributions to biotechnology have earned him several prestigious awards including the Biotechnology Heritage Award, Association for Molecular Pathology Award for Excellence in Molecular Diagnostics, Lemelson-MIT Prize for Innovation and Invention, Kyoto Prize in Advanced Technology and Lasker Prize.
Systems Approaches to Medicine and Cancer
-
- Informed Consent and Special Populations - 2010 (Session 7)
-
- - Christine Grady, Don Rosenstein and Maggie Little (2010/11/18)
- - Category : Bioethics
- Ethical and Regulatory Aspects of Clinical Research
Course Objectives
By the end of this course, participants will be able to:
Utilize a systematic framework for evaluating the ethics of a clinical research protocol.
Apply appropriate codes, regulations, and other documents governing the ethical conduct of human subject research to their own research.
Discuss controversial issues relating to human subject research, including Phase 1 research, randomization, children in research, international research, etc.
Identify the critical elements of informed consent and strategies for implementing informed consent for clinical research.
Describe the purpose, function, and challenges of IRBs.
Appreciate the experience of human subjects who have participated in research protocols.
For more information, visit
http://www.bioethics.nih.gov/hsrc/index.shtml
Informed Consent and Special Populations - 2010 (Session 7)